If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
Highlights strong Vibegron results in older men & real-world prostate cancer insights
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
